Market LIVE
Published markets; coverage varies by country
Product profile · United States

Lunsumio Velo

 ·  Patent Litigation & Settlement History ↓

Ingredientmosunetuzumab-axgb
Application typeBLA
Application761263
Product004
Dosage formInjection
RouteSubcutaneous
Strength45MG/ML
Approval date2025-12-19
Marketing statusPrescription
Status event—
ApplicantGENENTECH INC
Product source

Current GenericRadar decision

Year2036
SelectionCANDIDATE
ReviewFINAL_CHECKING
Anchor typeDRUG_SUBSTANCE
Anchor date2036-12-22
Patent anchor2036-12-22
Exclusivity anchor2034-12-22
Protection date—
First Final ANDA—
Status event—

GNR judgment: CANDIDATE. Reference year: 2036. Anchor type: DRUG_SUBSTANCE. Patent anchor: 2036-12-22. Exclusivity anchor: 2034-12-22. Anchor date: 2036-12-22. Patent tail: no. Exclusivity tail: no. Review status: FINAL_CHECKING. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
US111866502035-01-26— —NYDS_EQUIVALENT_SCOPE_SUPPORTED
English description not available.
———
US101741242036-12-22— —YNTRUE_DS_SCOPE_SUPPORTED
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
ODE2025-12-19—NN——Source
ODE2022-12-222029-12-22NN——Source
Orphan Exclusivity Exp. Date—2029-12-22————Source
RPE_BASELINE2022-12-222034-12-22Full-product 12-year operational assumption; not FDA determinationYY——Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (5)
TypeDateRoleBasisSource
PATENT2035-01-26OTHER_RIGHT_REFERENCEClassification includes excluded and conditional scope; use payload; current official term pendingSource
PATENT2036-12-22ANCHOR_REFERENCEClassification includes excluded and conditional scope; use payload; current official term pendingSource
REGULATORY_EXCLUSIVITY—SCOPE_HISTORYIndication-specific history; full coverage not assertedSource
REGULATORY_EXCLUSIVITY2029-12-22SCOPE_HISTORYIndication-specific history; full coverage not assertedSource
REGULATORY_EXCLUSIVITY2034-12-22SCOPE_HISTORYUser-adopted operational baseline; inherited dates do not restart RPE; not FDA determinationSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.